Smithfield Trust Co. Has $1.39 Million Position in Bristol-Myers Squibb Co (BMY)
Smithfield Trust Co. reduced its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 5.2% in the 3rd quarter, Holdings Channel reports. The firm owned 22,381 shares of the biopharmaceutical company’s stock after selling 1,230 shares during the quarter. Smithfield Trust Co.’s holdings in Bristol-Myers Squibb were worth $1,390,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Cypress Capital Management LLC WY increased its stake in Bristol-Myers Squibb by 154.7% during the third quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 1,160 shares during the last quarter. CSat Investment Advisory L.P. acquired a new stake in Bristol-Myers Squibb during the second quarter worth about $113,000. Landaas & Co. WI ADV acquired a new stake in Bristol-Myers Squibb during the second quarter worth about $131,000. Selective Wealth Management acquired a new stake in Bristol-Myers Squibb during the third quarter worth about $184,000. Finally, LFA Lugano Financial Advisors SA increased its stake in Bristol-Myers Squibb by 85.8% during the third quarter. LFA Lugano Financial Advisors SA now owns 3,207 shares of the biopharmaceutical company’s stock worth $199,000 after acquiring an additional 1,481 shares during the last quarter. Hedge funds and other institutional investors own 72.54% of the company’s stock.
A number of equities research analysts have recently issued reports on the company. ValuEngine upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, July 14th. Credit Suisse Group increased their target price on Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. BMO Capital Markets reiterated a “hold” rating on shares of Bristol-Myers Squibb in a research note on Sunday, July 22nd. Morgan Stanley lowered their target price on Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating for the company in a research note on Tuesday. Finally, Jefferies Financial Group set a $58.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Sunday, July 15th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $62.48.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.18. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. On average, research analysts anticipate that Bristol-Myers Squibb Co will post 3.88 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, November 1st. Investors of record on Friday, October 5th were issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date was Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.
COPYRIGHT VIOLATION WARNING: “Smithfield Trust Co. Has $1.39 Million Position in Bristol-Myers Squibb Co (BMY)” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://theolympiareport.com/2018/11/10/smithfield-trust-co-has-1-39-million-position-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
See Also: What is a Leveraged Buyout (LBO)?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.